+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Darbepoetin Alfa Market by Indication, End User, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Darbepoetin Alfa Market by Indication, End User, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Sale

Darbepoetin Alfa Market by Indication, End User, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968192
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Darbepoetin alfa is altering the standards of anemia management by combining glycoengineering with extended half-life technology. This evolution positions the product as a preferred therapy pathway for clinicians seeking to enhance patient adherence, delivery flexibility, and resource efficiency across high-need settings.

Market Snapshot: Darbepoetin Alfa Market Trends and Performance

The darbepoetin alfa market grew from USD 82.19 million in 2024 to USD 86.75 million in 2025. It is expected to continue growing at a CAGR of 5.34%, reaching USD 112.34 million by 2030. Expanding demand is underpinned by rising chronic kidney disease burden, increased adoption in oncology and viral-induced anemia, along with changing care delivery models and payer requirements worldwide.

Scope & Segmentation

This market research provides actionable insights into the product’s ecosystem, spanning technology, segments, and geographies. Major segmentation and definitions include:

  • Indications: Chronic kidney disease anemia, chemotherapy-induced anemia, anemia in HIV, anemia in hepatitis.
  • End User Settings: Home care, clinics, public hospitals, private hospitals.
  • Route of Administration: Intravenous (available as prefilled syringes and vials), subcutaneous (offered as prefilled syringes and vials).
  • Distribution Channels: Hospital pharmacy, retail pharmacy, online pharmacy for home delivery.
  • Dosage Forms: Prefilled syringe, cartridge, multiple dose vial.
  • Regions Included: Americas (US, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (select Western European, Middle Eastern, African countries), Asia-Pacific (China, India, Japan, Australia, South Korea, and more).
  • Key Companies: Amgen Inc., Pfizer Inc., Sandoz International GmbH, Viatris Inc., Fresenius Kabi AG, Intas Pharmaceuticals Limited, Biocon Limited, Aspen Pharmacare Holdings Limited, STADA Arzneimittel AG, Celltrion Healthcare Co., Ltd.

Key Takeaways for Decision-Makers

  • Advances in remote monitoring and digital adherence tools are fostering patient-centric home care and supporting reduction in hospital-based anemia management.
  • Tailored dosing protocols now optimize efficacy and limit adverse events, aiding roll-out among complex patient cohorts.
  • Subcutaneous self-administration and enhanced device ergonomics address demands for convenience and enable more outpatient care.
  • Payer-driven value-based contracts are influencing adoption, with an emphasis on linking clinical outcomes to reimbursement frameworks.
  • Regional variations in regulatory and access pathways make localized strategies essential for competitive positioning and sustained market access.
  • Strategic market growth is reinforced by co-promotion agreements, biosimilar partnerships, and integration of real-world evidence tools for rapid uptake of new protocols.

Tariff Impact: Responding to 2025 U.S. Supply Chain Changes

The 2025 introduction of new U.S. tariffs has raised the cost of imported raw materials and pharmaceutical ingredients, compelling manufacturers to reconsider procurement and localize production. Distributors are adapting inventory approaches, while payers negotiate updated reimbursement strategies. Organizational adaptability and cross-stakeholder collaboration are crucial for managing price fluctuations and safeguarding patient access during evolving policy circumstances.

Methodology & Data Sources

This research is anchored in comprehensive secondary data review (peer-reviewed articles, regulatory filings, proprietary databases) and primary interviews with clinicians, payers, and industry leaders. Quantitative data harmonization, triangulation, and expert peer review underpin insight reliability and consistency.

Why This Report Matters

  • Equips senior decision-makers with validated analysis of disruptions, competitive moves, and technology pathways influencing the darbepoetin alfa landscape.
  • Highlights actionable segment and regional opportunities to facilitate informed strategic planning and partnership development.

Conclusion

Darbepoetin alfa’s adoption trajectory is shaped by evolving care models, technological enhancement, and dynamic policy environments. This research enables stakeholders to respond decisively, optimize access, and realize sustained value in the global anemia management market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Darbepoetin Alfa Market, by Indication
8.1. Introduction
8.2. Anemia In Hepatitis
8.3. Anemia In HIV
8.4. Chemotherapy Induced Anemia
8.5. Chronic Kidney Disease Anemia
9. Darbepoetin Alfa Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Home Care
9.4. Hospitals
9.4.1. Private Hospitals
9.4.2. Public Hospitals
10. Darbepoetin Alfa Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.2.1. Prefilled Syringes
10.2.2. Vials
10.3. Subcutaneous
10.3.1. Prefilled Syringes
10.3.2. Vials
11. Darbepoetin Alfa Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Darbepoetin Alfa Market, by Dosage Form
12.1. Introduction
12.2. Cartridge
12.3. Multiple Dose Vial
12.4. Prefilled Syringe
13. Americas Darbepoetin Alfa Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Darbepoetin Alfa Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Darbepoetin Alfa Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Pfizer Inc.
16.3.3. Sandoz International GmbH
16.3.4. Viatris Inc.
16.3.5. Fresenius Kabi AG
16.3.6. Intas Pharmaceuticals Limited
16.3.7. Biocon Limited
16.3.8. Aspen Pharmacare Holdings Limited
16.3.9. STADA Arzneimittel AG
16.3.10. Celltrion Healthcare Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DARBEPOETIN ALFA MARKET MULTI-CURRENCY
FIGURE 2. DARBEPOETIN ALFA MARKET MULTI-LANGUAGE
FIGURE 3. DARBEPOETIN ALFA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DARBEPOETIN ALFA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DARBEPOETIN ALFA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DARBEPOETIN ALFA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHEMOTHERAPY INDUCED ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHRONIC KIDNEY DISEASE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CARTRIDGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MULTIPLE DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 56. CANADA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 58. CANADA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 59. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. ITALY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. ITALY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 131. ITALY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 132. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. QATAR DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. QATAR DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. QATAR DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. QATAR DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 187. QATAR DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 188. QATAR DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. POLAND DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. POLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. POLAND DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. POLAND DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. POLAND DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 251. POLAND DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 252. POLAND DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. CHINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. CHINA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. CHINA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. CHINA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 276. CHINA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 277. CHINA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. CHINA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 279. INDIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. INDIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. INDIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. INDIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. INDIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 284. INDIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. JAPAN DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 319. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 322. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 324. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. THAILAND DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Darbepoetin Alfa market report include:
  • Amgen Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Viatris Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Limited
  • Biocon Limited
  • Aspen Pharmacare Holdings Limited
  • STADA Arzneimittel AG
  • Celltrion Healthcare Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 86.75 Million
Forecasted Market Value ( USD ) by 2030 $ 112.34 Million
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Darbepoetin Alfa (Aranesp) Market Report 2025 - Product Image

Darbepoetin Alfa (Aranesp) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Darbepoetin Alfa (Aranesp) Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Darbepoetin Alfa (Aranesp) Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Anemia Drugs Market by Drug Class, Distribution Channel, Route of Administration, End User - Global Forecast to 2030 - Product Image

Anemia Drugs Market by Drug Class, Distribution Channel, Route of Administration, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Epoetin Alfa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Epoetin Alfa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Factor Xa Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From

About the Darbepoetin Alfa Market

Darbepoetin Alfa is a type of hematological drug used to treat anemia. It is a recombinant form of erythropoietin, a hormone produced naturally in the body that stimulates the production of red blood cells. Darbepoetin alfa is used to treat anemia caused by chronic kidney disease, chemotherapy, or HIV/AIDS. It is also used to reduce the need for red blood cell transfusions in patients with certain types of anemia. The Darbepoetin Alfa market is highly competitive, with a number of companies offering products. Some of the major players in the market include Amgen, Pfizer, Johnson & Johnson, Novartis, and Roche. These companies are engaged in research and development activities to develop new products and expand their product portfolios. They are also investing in marketing and promotional activities to increase their market share. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.